Noguchi Institute

Nishi-Tokyo-shi, Japan

Noguchi Institute

Nishi-Tokyo-shi, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
Noguchi Institute | Date: 2017-09-13

The present invention is a method for detecting at least one disease selected from the group consisting of visceral fat accumulation, hyperglycemia, dyslipidemia, hypertension and atherosclerosis or a disease two or more of which are combined or detecting onset risk of these diseases, which comprises(a) a step of measuring a ganglioside GM3 in a blood sample derived from a subject,wherein the ganglioside GM3 has a structure represented by the following formula (1).^(1) represents a glycan constituting the ganglioside GM3, and R^(2)-C(=O)- represents a fatty acid residue having 16 or more and 24 or less carbon atoms which may have a double bond, and having an OH group as a substituent.]


Kobata A.,Noguchi Institute
Proceedings of the Japan Academy Series B: Physical and Biological Sciences | Year: 2013

Many glycosidases, which work as useful reagents for the studies of structures and functions of free and conjugated oligosaccharides, have been found and thoroughly purified. These enzymes are classified into exo- and endoglycosidases by their glycon specificities. Their usefulness and limits as reagents are explained in detail in this review. Endoglycosidases, which were originally found in the culture fluid of bacteria and in the extracts of plants, are now widely found in the mammals including humans. The physiological roles of these enzymes are discussed in relation to the oligosaccharides accumulated in the urine of patients with exoglycosidase deficiencies. Furthermore, PNGase is found to play important roles in the ER-associated degradation pathway of glycoproteins. Recent studies of the glycosidases in Bifidobacteria have revealed that GNB/LNB pathway, which uniquely exist in this bacteria, works for the expression of Bifidus factor activity of human milk oligosaccharides, an important topic in the baby nutrition. This interesting field will be introduced in detail in one section of this article. © 2013 The Japan Academy.


Kobata A.,Noguchi Institute
Proceedings of the Japan Academy Series B: Physical and Biological Sciences | Year: 2010

Comparative study of the oligosaccharide profiles of individual human milk revealed the presence of three different patterns. Four oligosaccharides containing the Fucα1-2Gal group were missing in the milk of non-secretor, and three oligosaccharides containing the Fucα1-4GlcNAc group were missing in the milk of Lewis negative individuals. Disappearance of some major oligosaccharides in these samples led to the finding of five novel minor oligosaccharides, which were hidden under the missing oligosaccharides. Following these studies, structures of many novel milk oligosaccharides were elucidated. At least 13 core oligosaccharides were found in these oligosaccharides. By adding α-fucosyl residues and sialic acid residues to these core oligosaccharides, more than one hundred oligosaccharides were formed. All these oligosaccharides contain lactose at their reducing termini. This evidence, together with the deletion phenomena found in the milk oligosaccharides of non-secretor and Lewis negative individuals, suggested that the oligosaccharides are formed from lactose by the concerted action of glycosyltransferases, which are responsible for elongation and branching of the Galβ1-4GlcNAc group in the sugar chains of glycoconjugates on the surface of epithelial cells. Therefore, oligosaccharides in human milk could include many structures, starting from the Galβ1-4GlcNAc group in the sugar chains of various glycoconjugates. Many lines of evidence recently indicated that virulent enteric bacteria and viruses start their infection by binding to particular sugar chains of glycoconjugates on the target cell surfaces. Therefore, milk oligosaccharides could be useful for developing drugs, which inhibit the infection of bacteria and viruses. © 2010 The Japan Academy.


Patent
Noguchi Institute | Date: 2011-07-20

The present invention herein provides a proliferation inhibitor of H. pylori bacteria comprising a compound that can specifically inhibit the proliferation of H. pylori bacteria, which does not generate bacterium resistant, can be eaten, drunken or administrated safely for a long period of time, can be simply mass-manufactured and can be used for foods and beverages or pharmaceutical preparation. The proliferation inhibitor of H. pylori bacteria comprises an N-acetylglucosaminyl beta-linked monosaccharide derivative represented by the following chemical formula (1):GlcNAc1-beta-O-Y(1)wherein Y is an alkyl group, an alkoxyl group, an alkenyl group, an alkynyl group, an aralkyl group, an aryl group, a heteroaryl group, a carboxyl group or an alkoxycarbonyl group.


Patent
Noguchi Institute | Date: 2012-08-29

The problem is to provide a MALDI mass spectrometry method that can be used for a mass spectrometry method by a general MALDI method with which it is possible to measure multiple molecules to be measured that are contained in a sample quantitatively in a short period of time with good efficiency compared with conventional methods. The problem is solved by a MALDI mass spectrometry method for a sample containing multiple molecules to be measured, which is a MALDI mass spectrometry method characterized in that the multiple molecules to be measured are a saccharide mixture, a glycopeptide mixture, a glycopeptide-peptide mixture, a glycoprotein mixture, or a glycoprotein-protein mixture, and that a quantitative mass spectrum of the multiple molecules to be measured is obtained from an arbitrary point in the sample to be measured where a signal is detected without measuring and integrated averaging the entire sample to be measured.


Patent
Noguchi Institute | Date: 2013-01-09

A method for directly inhibiting proliferation of Helicobacter pylori bacteria, that includes administering to a subject infected with Helicobacter pylori an N-acetylglucosaminyl beta-linked monosaccharide represented by: GlcNAcl-beta-OY where Y is an alkyl group, an alkoxyl group, an alkenyl group, an alkynyl group, an aralkyl group, an aryl group, a heteroaryl group, a carboxyl group, or an alkoxycarbonyl group.


Patent
Noguchi Institute | Date: 2011-08-10

The present invention provides a method for detecting a glycan structure of a prostate specific antigen (PSA) rapidly and with high sensitivity and determining prostate carcinoma based on the difference in the structure, in particular, a method for determining between prostate carcinoma and benign prostatic hyperplasia accurately. A method for determining prostate carcinoma, wherein the method includes a step of analyzing a PSA glycan structure in a sample derived from a test subject, and prostate carcinoma is determinied in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(-)). Especially, a method for determining prostate carcinoma, wherein prostate carcinoma is determinied in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(-)), and benign prostatic hyperplasia is determined in the case of 30% or less.


Patent
Noguchi Institute | Date: 2014-07-09

The problem is to provide a MALDI mass spectrometry method that can be used for a mass spectrometry method by a general MALDI method with which it is possible to measure multiple molecules to be measured that are contained in a sample quantitatively in a short period of time with good efficiency compared with conventional methods. The problem is solved by a MALDI mass spectrometry method for a sample containing multiple molecules to be measured, which is a MALDI mass spectrometry method characterized in that the multiple molecules to be measured are a saccharide mixture, a glycopeptide mixture, a glycopeptide-peptide mixture, a glycoprotein mixture, or a glycoprotein-protein mixture, and that a quantitative mass spectrum of the multiple molecules to be measured is obtained from an arbitrary point in the sample to be measured where a signal is detected without measuring and integrated averaging the entire sample to be measured.


Patent
Noguchi Institute | Date: 2012-07-11

It is an object of the present invention to provide a method for producing an 11-sugar sialylglycopeptide easily and with good yield and a high degree of purity on an industrial scale from defatted bird egg yolks. The present invention provides a production method of an 11-sugar sialylglycopeptide. More specifically, the present invention provides a production method of an 11-sugar sialylglycopeptide comprising: an extraction step of extracting defatted bird egg yolks with water or a salt solution to obtain a liquid extract of a glycopeptide, a precipitation step of adding the liquid extract to a water-soluble organic solvent to precipitate the glycopeptide, and a desalting step of desalting the precipitate.


Patent
Noguchi Institute and Immuno Biological Laboratories Co. | Date: 2015-04-17

The present invention is aimed to provide a method for preparing an acceptor that is N-glycan hydrolyzed antibody or a Fc fragment thereof used for producing antibody having a homogeneous N-glycan structure; a method for determining a combination of endoglycosidases for use in said preparation; and a method for measuring N-glycans linked to an antibody. The present invention is directed to a method for producing a N-glycan hydrolyzed antibody or Fc fragment thereof, comprising reacting the antibody or the Fc fragment thereof with several endoglycosidases; and a method for determining quantitative information of an objective N-glycan with a desired structure linked to an antibody or a Fc thereof, comprising a protease treatment step and a glycopeptide measurement step, etc.

Loading Noguchi Institute collaborators
Loading Noguchi Institute collaborators